European societies expect science, technology and innovation to promote economic growth and improved wellbeing. Research alone is insufficient. Its translation into discoveries of new processes, services and products is vital. And evaluation of the impact of scientific and social sciences research can lead to better funding decisions.
The factors that lead to innovation are complex and evolve. We use evidence to untangle complexity, recognise connections, and open channels for new thought. Our research aims to maximise the gains that science, technology and innovation can bring to society and the economy.
Because of the growing demand for transparency and accountability in research evaluation, researchers developed a comprehensive list of evaluation tools and techniques and explained when each might be most useful and why. They then offered a list of 100 ideas for metrics that can be used to assess and communicate the value of biomedical research.
The Hong Kong University Grants Committee has appointed RAND Europe to help with the initial phase of a review of the Research Grants Council, to ensure funding is used and managed efficiently and meets the needs of Hong Kong.
Since 2014, UK Higher Education Funding Councils have used the Research Excellence Framework to assess the quality and impact of a university's research before providing further funding. ImpactFinder helps universities manage their research funding submissions and identify and review impact case studies.
The Cyber Security Capability Maturity Model allows organisations to map and assess maturity to achieve a healthy and resilient national cyber ecosystem. A new toolbox will aim to help policymakers identify priority areas for intervention to strengthen cyber capabilities.
The King’s Policy Institute, the Office of Health Economics and RAND Europe developed a methodology to estimate how many pounds of pharmaceutical industry R&D is stimulated in the UK by public or charity spending on medical research.
A research team from RAND Europe and several other organisations are evaluating the role of EU-funded R&D into poverty-related and neglected diseases, in particular examining contributions to achieving universal health coverage and improving population health in low and middle-income countries.